Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020)

Keros Therapeutics' Other Operating Expenses history spans 2 years, with the latest figure at -$1.5 million for Q1 2020.

  • For Q1 2020, Other Operating Expenses fell 146.69% year-over-year to -$1.5 million; the TTM value through Dec 2020 reached -$1.5 million, up 41.89%, while the annual FY2020 figure was -$1.5 million, 41.89% up from the prior year.
  • Other Operating Expenses reached -$1.5 million in Q1 2020 per KROS's latest filing, down from -$78000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$78000.0 in Q4 2019 to a low of -$1.5 million in Q1 2020.